Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Cited by (1,004)

Items 801–900 of 1,004

1. KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
   Daolin Tang, Guido Kroemer, Rui Kang · 2025 · BMJ Oncology
2. Therapeutic advances with KRASG12C inhibitors and combination strategies in non-small cell lung cancer brain metastases
   Debanjan Bhattacharya, Benjamin Roman, Sanjana Reddy · 2026 · Cancer Gene Therapy
3. KRAS-targeted therapy in the treatment of non-small cell lung cancer
   Jina Yun, Reid Nakagawa, Kenneth W. Tham · 2022 · Journal of Oncology Pharmacy Practice
4. Top advances in lung cancer, 2021
   Nisha Anjali Mohindra, Jyoti D. Patel · 2022 · Cancer
5. TARGET National: A UK-wide Liquid-based Molecular Profiling Programme
   Ana Ortega-Franco, E. Darlington, Alastair Greystoke, Matthew Krebs · 2022 · Clinical Oncology
6. Molecular-Guided Off-Label Targeted Therapy in a Large-Scale Precision Oncology Program
   Vishal Vashistha, Evangelia Katsoulakis, Aixia Guo, Meghan J. Price, Sara Ahmed, Michael J. Kelley · 2023 · JCO Precision Oncology
7. Nueva actualización de las recomendaciones para la determinación de biomarcadores predictivos en el carcinoma de pulmón no célula pequeña: Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica
   Dolores Isla, María D. Lozano, Luis G Paz-Ares, Clara Salas, Javier de Castro, Esther Conde, Enriqueta Felip, Javier Gómez‐Román, Pilar Garrido, Ana B. Enguita · 2023 · Revista Española de Patología
8. CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code
   Shannon S. Zhang, Alexandria TM Lee, Misako Nagasaka · 2023 · Lung Cancer Targets and Therapy
9. CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
   Danielle Brazel, Jennifer Kim, Sai‐Hong Ignatius Ou · 2023 · Lung Cancer Targets and Therapy
10. The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation
    Sun Young Jeong, Jung Yong Hong, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Jae Yeon Jang, Youngkyung Jeon, Seung Tae Kim · 2023 · Therapeutic Advances in Gastroenterology
11. Nucleic Acid Quality Assessment is Critical to the Success of the Oncomine Dx Target Test for Lung Cancer
    Yuki Nagakubo, Yosuke Hirotsu, Kenji Amemiya, Hitoshi Mochizuki, Toshiharu Tsutsui, Yumiko Kakizaki, Yoshihiro Miyashita, Rumi Higuchi, Takahiro Nakagomi, Taichiro Goto et al. · 2023 · Molecular Diagnosis & Therapy
12. Real-world outcomes in patients with KRAS G12C–mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond
    Jhanelle E. Gray, Hil Hsu, Diana Younan, Gaurav Suri, Victoria Chia, Alexander I. Spira, Melissa Lynne Johnson · 2023 · Lung Cancer
13. Gantt chart for updated OS and PFS after cancer targeted therapy
    Xiaojing Du, Xiaoling Lü, Xin Cao · 2023 · The Innovation Medicine
14. KRAS G12C mutation: from undruggable target to potentially agnostic biomarker
    Badi Edmond El Osta · 2023 · Translational Lung Cancer Research
15. Concordance between cryobiopsy and forceps biopsy specimens in assessment of immunohistochemistry staining for non-small cell lung carcinoma
    Kanako Nishimatsu, Yuji Matsumoto, Jumpei Kashima, Tatsuya Imabayashi, Keigo Uchimura, Hideaki Furuse, Ken Masuda, Yuki Shinno, Yusuke Okuma, Tsutomu Yoshida et al. · 2023 · Translational Lung Cancer Research
16. Improvement of patient care using cancer genomic profiling: SCRUM-/CIRCULATE-Japan experience
    Atsushi Ohtsu, Kōichi Goto, Takayuki Yoshino · 2023 · Proceedings of the Japan Academy Series B
17. RAS isoform specific activities are disrupted by disease associated mutations during cell differentiation
    Rohan Chippalkatti, Bianca Parisi, Farah Kouzi, Christina Laurini, Nesrine Ben Fredj, Daniel Abankwa · 2024 · European Journal of Cell Biology
18. Leveraging Cancer Phenotypic Plasticity for Novel Treatment Strategies
    Sravani Keerthi Ramisetty, Ayalur Raghu Subbalakshmi, Siddhika Pareek, Tamara Mirzapoiazova, Dana Do, Dhivya Prabhakar, Evan P. Pisick, Sagun Shrestha, Srisairam Achuthan, S. Bhattacharya et al. · 2024 · Journal of Clinical Medicine
19. KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors
    Linyan Tian, Chengming Liu, Sufei Zheng, Huiyang Shi, Wei Fang, Wenxin Jiang, Yucheng Dong, Haiyan Xu, Enzhi Yin, Nan Sun et al. · 2025 · Journal of Translational Medicine
20. Liquid Biopsy Biomarkers for Immunotherapy in Non-Small Cell Lung Carcinoma: Lessons Learned and the Road Ahead
    Jesus Hita-Millan, Ángel Carracedo, Ceres Fernández–Rozadilla · 2021 · Journal of Personalized Medicine
21. Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer
    Sofie Claerhout, Stefan Lehnert, Sara Vander Borght, Lien Spans, Christophe Dooms, Els Wauters, Johan Vansteenkiste, Birgit Weynand, Karen Deraedt, Claire Bourgain et al. · 2022 · Lung Cancer
22. Analysis of histology-agnostic targets among soft tissue and bone sarcomas in the AACR GENIE database
    Roberto Carmagnani Pestana, César Serrano · 2023 · Frontiers in Oncology
23. Nanotechnology – a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer
    Filip Gorachinov, Fatima Mraiche, Diala Alhaj Moustafa, Ola Hishari, Yomna Ismail, Jensa Mariam Joseph, Maja Simonoska Crcarevska, Marija Glavaš Dodov, Nikola Geškovski, Katerina Goračinova · 2023 · Beilstein Journal of Nanotechnology
24. Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer
    Jacobi B. Hines, Benjamin Bowar, Emma Edelman Levine, Alessandra Esposito, Marina Chiara Garassino, Christine M. Bestvina · 2023 · International Journal of Molecular Sciences
25. Targeting microbiome, drug metabolism, and drug delivery in oncology
    Ai Sumiyoshi, Hiroyuki Fujii, Yusuke Okuma · 2023 · Advanced Drug Delivery Reviews
26. Covalent Rescue of Mutant p53
    David Philip Lane, Chandra Shekhar Verma · 2023 · Cancer Discovery
27. Advances in Non-Small Cell Lung Cancer (NSCLC) Treatment—A Paradigm Shift in Oncology
    Azhar Ali · 2024 · Pharmaceuticals
28. Differential Response and Resistance to KRAS-Targeted Therapy
    Liu, Zhaojin, Lenz, Heinz‐Josef, Yu, Jian, Zhang, Lin · 2025 · Molecular Carcinogenesis
29. Harnessing the potential of reverse‐phase protein array technology: Advancing precision oncology strategies
    Mari Masuda, Riko Nakagawa, Tadashi Kondo · 2024 · Cancer Science
30. New Targeted Therapies for Metastatic Non–Small Cell Lung Cancer
    Gregory J. Riely · 2024 · Journal of the National Comprehensive Cancer Network
31. KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review
    Min Tang, Yijun Wu, Xiufeng Bai, You Lü · 2024 · OncoTargets and Therapy
32. Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing
    Sara El Zaitouni, Abdelilah Laraqui, Meriem Ghaouti, Asmae Benzekri, Fouad Kettani, Youssra Boustany, Soukaina Benmokhtar, Hafsa Lamrani Alaoui, Hicham El Annaz, Rachid Abi et al. · 2024 · Technology in Cancer Research & Treatment
33. Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancer
    Jordyn Paige Higgins, Jennifer Wilkinson Carlisle, Nader H. Moniri, Shruti Gupta, Eziafa Oduah, Ticiana A.B. Leal · 2024 · Future Oncology
34. Personalized approaches to lung cancer treatment: A review of targeted therapies, pharmacogenomics, and combination strategies
    M. Tabrizi Namini, G. Bhagya, Manjari Sharma · 2025 · Aspects of Molecular Medicine
35. Blocking C-terminal processing of KRAS4b via a direct covalent attack on the CaaX-box cysteine
    Anna E. Maciag, Yue Yang, Alok K. Sharma, David M. Turner, Caroline J. DeHart, Hazem Abdelkarim, Lixin Fan, Brian P. Smith, Vandana Kumari, Marcin D. Dyba et al. · 2025 · Proceedings of the National Academy of Sciences
36. Is KRAS (G12C) inhibitor monotherapy for non-small cell lung cancer possible? A review of current literature
    Jian Zeng, Wenmei Jiang, Leilei Wu · 2025 · Journal of Translational Research
37. Acoustic ejection mass spectrometry: An integrated pipeline for ultra-high throughput screening, reactivity profiling, and potency analysis of covalent BTK inhibitors
    Ronghai Cheng, Adil Muneer, Maria Hercher, Bekim Bajrami, Reza Nemati · 2025 · SLAS TECHNOLOGY
38. Targeting KRAS in colorectal cancer (Review)
    Minjie Zhang, Dawei Wu, Charlene Yu Lin Tang, Li Zhang, Shuquan Zhang, Wei Li, Ning Li, Xinhua Yan · 2025 · Molecular and Clinical Oncology
39. Adagrasib in the treatment of colorectal cancer
    Sara F. Haddad, Youssef Bouferraa, Kanika G. Nair · 2025 · Future Oncology
40. Promise and Challenge of β-Lactone Electrophiles to Target Aspartate 12 of Mutant KRASG12D
    Balázs Budai, Andrea Vaupel, Callum J. Dickson, Kim S. Beyer, Daniel Alexander Guthy, Nils Ostermann, Lynn M. McGregor, Ruben de Kanter, Andreas Weiss, Markus Linder et al. · 2025 · Journal of Medicinal Chemistry
41. Specific inhibitor to KRASG12C induces tumor-specific immunity and synergizes with oncolytic virus for enhanced cancer immunotherapy
    Zhi Zhu, Hongqi Chen, Chao Feng, Lingjuan Chen, Congrong Ma, Zuqiang Liu, Zhaoxia Qu, David L. Bartlett, Binfeng Lu, Kai Li et al. · 2025 · Journal for ImmunoTherapy of Cancer
42. Optimizing KRAS Therapeutics for Non–Small Cell Lung Cancer
    Jeong Uk Lim, Marcelo Vailati Negrao, David S. Hong · 2025 · Annual Review of Medicine
43. Clinical Actionability of Genes in Gastrointestinal Tumors
    Nadia Saoudi Gonzalez, Giorgio Patelli, Giovanni Crisafulli · 2025 · Genes
44. Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors
    Lihao Wang, Dandan Wei, Shanshan Li, Shiqing Jiang · 2025 · Discover Oncology
45. Peptide-Based Targeted Covalent Inhibitors
    Fangyu Cao, Ruo-Chen Guo, Zeyu Zhang, Zhilin Yu · 2025 · ACS Applied Materials & Interfaces
46. Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors
    Yaakov E. Stern, Pompom Ghosh, John Peroza, Hitendra Singh Solanki, Denis J. Imbody, Liznair Bridenstine, Thiyagamurthy Pandurangan, Sylvia M. Frydman, Kathryn N. Nickens, Hannah L. Walker-Mimms et al. · 2025 · Cancer Research
47. Clinical and Molecular Characteristics of KRAS Codon-Specific Mutations in Advanced Pancreatic Ductal Adenocarcinoma with Prognostic and Therapeutic Implications
    Dongwoo Cho, Kabsoo Shin, Tae Ho Hong, Sung Hak Lee, Young-Hoon Kim, In-Ho Kim, Sook Hee Hong, Myung Ah Lee, Se Jun Park · 2025 · International Journal of Molecular Sciences
48. CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer
    Szu-Aun Lim, Haley Todd, Grace Goodhart, Wen-Hsuan Chang, Amber M. Amparo, Rachel Bridgens, Julien Dilly, Se Jun Park, Robert M. Beal, Sara M. Shehadeh et al. · 2025 · Cancer Research
49. Identification and characterization of binders to a cryptic and functional pocket in KRAS
    Kim S. Beyer, Jessica Klein, Stéphanie Katz, Patrick Welker, Mylene Lanter, Daniel Alexander Guthy, Kerstin Pollehn, Aurélie Gluck-Gadé, Melusine Bleu, Jessica Desogus et al. · 2025 · Nature Communications
50. Molecular Testing for Intrahepatic Cholangiocarcinoma: What, When, How?
    Maryam Barsch, Elaine-Pashupati Dopfer, Anne Maria Schultheis, Michael Quante · 2026 · Journal of Gastrointestinal Cancer
51. CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer
    Antonio Mulero‐Sánchez, Astrid R. Bosma, Bonifiya Visuvasam, Niki Pouliopoulou, Marieke van de Ven, Natalie Proost, Manon Boeije, Cor Lieftink, Roderick L. Beijersbergen, René Bernards et al. · 2026 · Journal of Experimental & Clinical Cancer Research
52. Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C
    Nicholas Endres, Steven Do, Rana M Mroue, Jack A. Terrett, Matt Saabye, Angela Oh, Thomas Hunsaker, Emily Chan, John C. Tran (1471192), Lan K. Nguyen et al. · 2026 · Journal of Medicinal Chemistry
53. Developments in systemic therapies for the management of lung cancer
    Sarah Heynemann, Paul L R Mitchell · 2021 · Internal Medicine Journal
54. Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia
    Hironori Arai, Yosuke Minami, SungGi Chi, Yoshikazu Utsu, Shinichi Masuda, Nobuyuki Aotsuka · 2022 · Biomedicines
55. Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer
    Stefania Belli, Ada Pesapane, Alberto Servetto, Daniela Esposito, Fabiana Napolitano, Claudia Maria Ascione, Alessandra Allotta, Nicola Zambrano, Federica Zito Marino, Renato Franco et al. · 2023 · British Journal of Cancer
56. Integrative multi-omic sequencing reveals the MMTV-Myc mouse model mimics human breast cancer heterogeneity
    Carson D. Broeker, Mylena M.O. Ortiz, Michael S. Murillo, Eran R. Andrechek · 2023 · Breast Cancer Research
57. Bioinformatics and Experimental Validation for Identifying Biomarkers Associated with AMG510 (Sotorasib) Resistance in KRASG12C-Mutated Lung Adenocarcinoma
    Peng Lin, Wei Cheng, Xin Qi, Pinglu Zhang, Jianshe Xiong, Jing Li · 2024 · International Journal of Molecular Sciences
58. Myotubularin-related-protein-7 inhibits mutant (G12V) K-RAS by direct interaction
    Philip Weidner, Daniel Saar, Michaela Söhn, Torsten Schroeder, Yanxiong Yu, Frank Gerrit Zöllner, Norbert Ponelies, Xiaobo Zhou, André Zwicky, Florian N. Rohrbacher et al. · 2024 · Cancer Letters
59. Comparison of diagnostic performance between Oncomine Dx target test and AmoyDx panel for detecting actionable mutations in lung cancer
    Yuki Nagakubo, Yosuke Hirotsu, Mona Yoshino, Kenji Amemiya, Ryota Saito, Yumiko Kakizaki, Toshiharu Tsutsui, Yoshihiro Miyashita, Taichiro Goto, Masao Omata · 2024 · Scientific Reports
60. Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer
    Xinan Wang, Kangcheng Hou, Biagio Ricciuti, Joao V. Alessi, Xihao Li, Federica Pecci, Rounak Dey, Jia Luo, Mark Magdi Awad, Alexander Gusev et al. · 2024 · Human Genetics and Genomics Advances
61. Prognostic value of KRAS G12C in advanced non-small cell lung cancer with high PD-L1 expression treated with upfront immunotherapy: a systematic review and meta-analysis
    Caroline-Claudia Erhart, Marco Cefalì, Dylan Mangan, Benjamin Kasenda, Luicano Wannesson · 2024 · Swiss Medical Weekly
62. Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation
    Vida Tajiknia, Maximilian P. Pinho-Schwermann, Praveen R. Srinivasan, Liz J. Hernández Borrero, Leiqing Zhang, Kelsey E. Huntington, Wafik S. El‐Deiry · 2024 · American Journal of Cancer Research
63. Advances in the Management of Lung Cancer Brain Metastases
    Kathryn Hockemeyer, Chad G. Rusthoven, Luke Pike · 2024 · Cancers
64. Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer
    Ofra Novoplansky, Sankar Jagadeeshan, Manu Prasad, Ksenia M. Yegodayev, Divyasree Marripati, Raghda Abu Shareb, Yariv Greenshpan, Sooraj Mathukkada, Talal Ben Lulu, Baisali Bhattacharya et al. · 2024 · Journal of Experimental & Clinical Cancer Research
65. Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy
    Brian Warnecke, Misako Nagasaka · 2024 · Drug Design Development and Therapy
66. Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS -Mutant Non–Small Cell Lung Cancer
    Mitchell S. von Itzstein, Timothy Francis Burns, Jonathan E. Dowell, Leora Horn, D. Ross Camidge, Sally Jane York, Keith D. Eaton, Kelly Kyle, Farjana Jahan Fattah, Jialiang Liu et al. · 2024 · Clinical Cancer Research
67. The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRAS G12C Inhibitors in Preclinical Models
    Nathan M. Jameson, Daehwan Kim, Catherine Lee, Blake Skrable, Alexandra Shea, Xiao Guo, Hooman Izadi, Mona Abed, Olivier Harismendy, Jianhui Ma et al. · 2025 · Cancer Research Communications
68. Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics
    Gerhard Hamilton, Adelina Plangger · 2021 · Expert Opinion on Drug Metabolism & Toxicology
69. Enhancing the Therapeutic Efficacy of KRASG12C Inhibitors in Lung Adenocarcinoma Cell Models by Cotargeting the MAPK Pathway or HSP90
    Ying Liu, Lei Wu, Hong Lü, En Wu, Jun Ni, Xiaorong Zhou · 2021 · Journal of Oncology
70. An In Vivo Inflammatory Loop Potentiates KRAS Blockade
    Kristina A. M. Arendt, Giannoula Ntaliarda, Vasileios Armenis, Danai Kati, Christin Henning, Georgia A. Giotopoulou, Mario A. A. Pepe, Laura Valentina Klotz, Anne‐Sophie Lamort, Rudolf Alexander Hatz et al. · 2022 · Biomedicines
71. Caspase-8 mutants activate Nrf2 via phosphorylating SQSTM1 to protect against oxidative stress in esophageal squamous cell carcinoma
    Lei Li, Riyue Feng, Yang Li, Xiao Yu, Yuhao Liu, Yahui Zhao, Zhihua Liu · 2022 · Free Radical Biology and Medicine
72. Enhancing an Oxidative “Trojan Horse” Action of Vitamin C with Arsenic Trioxide for Effective Suppression of KRAS-Mutant Cancers: A Promising Path at the Bedside
    Agata N. Burska, Bayansulu Ilyassova, Aruzhan Dildabek, Medina Khamijan, Динара Бегимбетова, Ferdinand Molnár, Dos D. Sarbassov · 2022 · Cells
73. A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice
    Yanxia Liu, Yuan Jiao Gao, Ying Wang, Cong Zhao, Zhiyun Zhang, Baolan Li, Tongmei Zhang · 2022 · BMC Cancer
74. Metabolic targeting, immunotherapy and radiation in locally advanced non-small cell lung cancer: Where do we go from here?
    Annika Dhawan, Phillip M. Pifer, Vlad Constantin Sandulache, Heath Devin Skinner · 2022 · Frontiers in Oncology
75. Efficacy of Immunotherapy in Second-Line Treatment of KRAS-Mutated Patients with Non-Small-Cell Lung Cancer—Data from Daily Practice
    Magdalena Knetki‐Wróblewska, Sylwia Tabor, Adam Płużański, Zofia Lewandowska, Andrzej Tysarowski, Hubert Pawlik, Dariusz Mirosław Kowalski, Maciej Jerzy Krzakowski · 2022 · Current Oncology
76. TargetingKRAS G12Cmutations in colorectal cancer
    Minghe Zhao, Aiwen Wu · 2022 · Gastroenterology report
77. With a little help from my T friends: T cells increase efficacy of KRAS (G12D) inhibitors
    Sara Mainardi · 2023 · Cell Reports Medicine
78. The role of targeted therapy and immune therapy in the management of non-small cell lung cancer brain metastases
    Cole Billena, Mina Lobbous, Christine A. Cordova, David M. Peereboom, Alejandro Torres-Trejo, Timothy An-thy Chan, Erin Sennett Murphy, Samuel T. Chao, John H. Suh, Jennifer S. Yu · 2023 · Frontiers in Oncology
79. The application of pancreatic cancer organoids for novel drug discovery
    Michael Karl Melzer, Yazid J. Resheq, Fatemeh Navaee, Alexander Kleger · 2023 · Expert Opinion on Drug Discovery
80. Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report
    Sindu Iska, Evan W. Alley · 2023 · Case Reports in Oncology
81. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
    Parneet Kaur Cheema, Shantanu Otto Banerji, Normand Blais, Quincy Siu-Chung Chu, Rosalyn Anne Juergens, Natasha B. Leighl, Adrian G. Sacher, Brandon S. Sheffield, Stephanie Leann Snow, Mark David Vincent et al. · 2023 · Current Oncology
82. The inhibition of pancreatic cancer progression by K-Ras-overexpressing mesenchymal stem cell-derived secretomes
    Qingji Huo, Kexin Li, Xun Sun, Adam Zhuang, Kazumasa Minami, Keisuke Tamari, Kazuhiko Ogawa, Melissa L. Fishel, Bai‐Yan Li, Hiroki Yokota · 2023 · Scientific Reports
83. Brief Report: Real-World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C-Mutated NSCLC
    Katherine Ismei Zhou, Chenyu Lin, Chin‐Lin Tseng, Nithya Ramnath, Jonathan E. Dowell, Michael J. Kelley · 2024 · JTO Clinical and Research Reports
84. Implementation of the ESMO-Magnitude of Clinical Benefit Scale: real world example from the 2022 Israeli National Reimbursement Process
    Ido Wolf, Barliz Waissengrin, Alona Zer, Rinat Bernstein‐Molho, Keren Rouvinov, Joel Cohen, Nathan I. Cherny, Gil Bar‐Sela · 2022 · ESMO Open
85. Setting the Benchmark for KRAS G12C -Mutated NSCLC
    Antonio Passaro, Solange Peters · 2022 · New England Journal of Medicine
86. The KRYSTAL-1 study of adagrasib — a new trial for KRASG12C-mutated non-small-cell lung cancer
    Yonina R. Murciano‐Goroff, Piro Lito · 2022 · Nature Reviews Clinical Oncology
87. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)
    Dinah V. Parums · 2022 · Medical Science Monitor
88. SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinoma
    Brianna R. Daley, Nancy E. Sealover, Erin Sheffels, Jacob M. Hughes, Daniel Gerlach, Marco H. Hofmann, Kaja Kostyrko, Barbara Mair, Amanda J. Linke, Zaria Beckley et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
89. KRAS G12C inhibitors: also a new promising new targeted therapy in advanced pancreatic adenocarcinoma?
    Marie Müller, David Tougeron · 2023 · Translational Cancer Research
90. Distinct small molecule inhibitors of Kras specifically prime CTLA4 blockade therapy to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancer
    Krishnan K. Mahadevan, Ana S. Maldonado, Bingrui Li, Aaron A. Bickert, Adrian Perdyan, Shreyasee V. Kumbhar, Sujan Piya, Amari M. Sockwell, Sami J. Morse, Kent A. Arian et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
91. Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers
    Theardy, Madelaine S., Takeda, Mitsunobu, Sorokin, Alexey, Chen, Shuaitong, Yang, Zecheng, Wang, Xiaofei, Kanikarla, Preeti, Coker, Oluwadara, Nguyen, Phuoc, Wei, Yongkun et al. · 2025 · Cell Reports Medicine
92. The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD‐L1 expression
    Xiaoqian Jing, Zhiping Luo, Jiayan Wu, Feng Ye, Jianfang Li, Zijia Song, Yaqi Zhang, Minmin Shi, Huaibo Sun, Yi Fang et al. · 2023 · Cancer Medicine
93. Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the United States
    Ya-Ning Zhu, Meng Xiong Tang, Ke-Xin Sun, Bei Gao, Xian-Peng Shi, Peng Zhang · 2024 · Frontiers in Pharmacology
94. Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation
    Divyan Chopra, Zhiyi Lan, David Michael Waterhouse, Jürgen Wolf, Enriqueta Felip, Hoora Moradian, Nadia Karim, Cynthia Chinedu Obiozor, Björn Stollenwerk · 2025 · Advances in Therapy
95. Navigating the complexities of pancreatic ductal adenocarcinoma: A review on therapeutic models and RAS inhibitors
    Sara Barrambana, Elena Zamorano-Domínguez, Vasiliki Liaki, Carmen E. Guerra · 2025 · Advanced Drug Delivery Reviews
96. Interaction Mechanisms of KRAS G12C Inhibitors (Sotorasib and Adagrasib) with Human Serum Albumin: Insights from Spectroscopic and Molecular Docking Studies
    Junsong Qin, Zhepeng Chen, Chuangyan Wang, Mai Lin, Xian Wang, Junfeng Li, Hui Liu, Yun Song · 2025 · Molecules
97. WEE1 inhibitor exerts synergistic effect with KRAS G12C inhibitor via MYBL2-RRM2 axis in KRASG12C-mutant lung cancer
    Chao Zhou, Yuqing Liu, Hongyu Liu, Jun Lü, Bo Zhang, Liang Zhu, Shuyuan Wang, Hui-min Lei, Baohui Han · 2025 · Cell Death and Disease
98. Liquid Biopsy in Lung Cancer: Tracking Resistance to Targeted Therapies
    Scarlet B. Urtecho, B. Munárriz, Mary Rose Rabey, Natasha B. Leighl · 2025 · Cancers
99. Broad-Spectrum RAS Inhibition in Pancreatic Ductal Adenocarcinoma: Mechanistic Advances and Therapeutic Promise
    Fawaz E. Alanazi, Yasser M. Alatawi, Abdullah Alattar, Reem Alshaman, Ahmed A. Kotb, ‏Helal F. Hetta · 2025 · Pharmaceuticals
100. Resistance to the KRASG12D Inhibitor MRTX1133 Is Associated with Increased Sensitivity to BET Inhibition
     Daniel R. Principe, Jeffrey H. Becker, Anastasia E. Metropulos, Alejandra M. Marinelarena, Thao D. Pham, Alexandre F. Aissa, Hidayatullah G. Munshi · 2026 · Molecular Cancer Therapeutics